Mobile

An open-label, multi-center, 24-month extension study to evaluate the safety of ranibizumab as symptomatic treatment for visual impairment due to diabetic macular edema in patients who have completed ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-007467-17

An open-label, multi-center, 24-month extension study to evaluate the safety of ranibizumab as symptomatic treatment for visual impairment due to diabetic macular edema in patients who have completed the RESTORE trial

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this trial is to evaluate the ocular and non-ocular adverse events during the 24-months study period in patients treated with Lucentis (0.5 mg)

Critère d'inclusion

  • Diabetic Macular Edema (DME)

Liens